Kowa Company Limited

Other

Yasuo Shinoda

Toshio Inagi

Hiroyuki Kawashima

Hiroyuki Shirai

Hirofumi Takeuchi

Makoto Kanebako

Toyojiro Muramatsu

Hiroshi Miura

Masayuki Kanishi

Masami Serizawa

Niichiro Takano

Katsumi Mashita

Hideatsu Takeuchi

Hironori Sassa

Tatsuya Nakai

Yoshio Tanizawa

A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of &#xb1;40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2&#x3b8;) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.

Composition containing medicine extremely slightly soluble in water and method for preparation thereof

An object of the present invention is to provide an indomethacin external preparation that has an excellent use feeling and excellent absorbability and causes no phase separation into an oil layer and an aqueous layer, thus exhibiting satisfactory stability of preparation with time. Provided is an indomethacin external preparation containing: 0.1 to 3 wt % of indomethacin; 25 to 50 wt % of alcohol; 0.01 to 5 wt % of gelling agent; 5 to 30 wt % of oil component; 20 to 50 wt % of water; and 0.01 to 10 wt % of one or more components selected from the group consisting of glyceryl monostearate, sorbitan monostearate, stearyl alcohol, and polyethylene glycol monostearate.

Indomethacin external preparation

The invention provides a solid dispersion composition containing 2-benzyl-5-(4-chlorophenyl)-6-&lsqb;4-(methylthio)phenyl&rsqb;-2H-pyridazin-3-one, hydroxypropylmethyl cellulose, and polyoxyethylene polyoxypropylene glycol. The solid dispersion composition of the present invention exhibits the excellent dissolvability of 2-benzyl-5-(4-chlorophenyl)-6-&lsqb;4-(methylthio)phenyl&rsqb;-2H-pyridazin-3-one in water, and enables this compound to be constant sequentially and thereby improve absorbability in blood.

Solid dispersion composition

Disclosed is a pharmaceutical composition comprising (E)-3,5-dihydroxy-7-&lsqb;4&prime;-4&Prime;-fluorophenyl-2&prime;-cyclopropyl-quinolin-3&prime;-yl&rsqb;-6-heptenoic acid, or its salt or ester, of which the aqueous solution or dispersion has pH of from 6.8 to 8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long.

Stable pharmaceutical composition

Growing community of inventors

Shizuoka, Japan

Yasuo Shinoda